Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

1.9K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.9K
Analgesia and Pain Management01:25

Analgesia and Pain Management

811
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
811
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

438
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
438
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.8K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

3.5K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
3.5K
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

373
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
373

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Multiplex engineering of Candida tropicalis for efficient production of astaxanthin" [Bioresour. Technol. 454 (2026) 134718].

Bioresource technology·2026
Same author

Multiplex engineering of Candida tropicalis for efficient production of astaxanthin.

Bioresource technology·2026
Same author

GM-CSF and M-CSF Driven Differentiation Differentially Regulates Chikungunya Virus Infection and Antiviral Responses in Human Monocyte-Derived Macrophages.

bioRxiv : the preprint server for biology·2026
Same author

Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Nutrients·2026
Same author

Collaborative Interface Engineering of the WO<sub>3</sub>-MoO<sub>3</sub> Heterostructure Enabling Accelerated CO<sub>2</sub> Cycloaddition with Epoxides.

Inorganic chemistry·2026
Same author

Chinese healthy eating index as a measure of diet quality and its association with depression and anxiety symptoms among people living with HIV: a cross-sectional study in China.

Frontiers in nutrition·2026
Same journal

Inhibition of Lin-11, Isl-1, and Mec‑3 Kinase (LIMK) Activity Attenuates Astrogliosis and Vascular Remodeling in an Experimental Model of Cuprizone-Induced Demyelination in Mice.

ACS pharmacology & translational science·2026
Same journal

Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance.

ACS pharmacology & translational science·2026
Same journal

Sertraline Enhances Bacterial Control without Adversely Affecting the Pharmacodynamic-Pharmacokinetic Properties of Frontline Tuberculosis Drugs.

ACS pharmacology & translational science·2026
Same journal

Repurposing FDA-Approved Drugs as Potential Inhibitors of Feline Infectious Peritonitis Virus 3CL<sup>pro</sup>: An Integrated In Silico and In Vitro Study with Synergistic Combination Analysis.

ACS pharmacology & translational science·2026
Same journal

Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems.

ACS pharmacology & translational science·2026
Same journal

Head-to-Head Comparison of Monomeric, Homodimeric, and Heterodimeric Fibroblast Activation Protein-Targeting Radioligands Based on Small Molecule Inhibitor and Cyclic Peptide.

ACS pharmacology & translational science·2026
See all related articles

Related Experiment Video

Updated: Sep 15, 2025

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.6K

Rational Design Biased Compounds against μ‑Opioid Receptor.

Chenyang Wu1,2, Yi Li3, Horst Vogel1,4,5

  • 1The Research Center for Computer-Aided Drug Discovery, The Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.

ACS Pharmacology & Translational Science
|July 17, 2025
PubMed
Summary
This summary is machine-generated.

Researchers designed novel biased opioid receptor ligands to reduce side effects. These molecules target the μ-opioid receptor (MOR) and favor G protein signaling over β-arrestin, paving the way for safer pain relief.

Keywords:
G protein biased signalingG protein-coupled receptorscomputational designmu-opioid receptorpartial agonist

More Related Videos

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

2.8K
Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
10:13

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding

Published on: June 9, 2017

16.6K

Related Experiment Videos

Last Updated: Sep 15, 2025

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.6K
Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

2.8K
Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
10:13

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding

Published on: June 9, 2017

16.6K

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Computational Biology

Background:

  • μ-opioid receptor (MOR) agonists are potent analgesics but cause side effects.
  • β-arrestin signaling contributes to adverse effects of MOR agonists.
  • Developing safer analgesics requires biased MOR ligands.

Purpose of the Study:

  • To design novel MOR ligands with biased G protein signaling.
  • To investigate the molecular mechanism of G protein subtype preference.
  • To guide the development of next-generation MOR analgesics with reduced side effects.

Main Methods:

  • In silico drug design and virtual screening.
  • Cell-based functional assays for receptor signaling.
  • Computational modeling of ligand-MOR interactions.
  • Analysis of G protein subtype bias.

Main Results:

  • Novel structural scaffolds with high affinity for MOR were designed.
  • Ligands demonstrated bias towards G protein signaling over β-arrestin.
  • Computational methods elucidated the molecular basis for G protein subtype preference.
  • Insightful view into ligand-MOR binding modes was provided.

Conclusions:

  • Biased MOR ligands can be designed using computational and experimental approaches.
  • Understanding G protein subtype preference is key to reducing adverse effects.
  • These findings facilitate the development of safer analgesics targeting the MOR.